Iradimed (NASDAQ:IRMD - Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Iradimed has set its FY 2024 guidance at 1.520-1.620 EPS and its Q1 2024 guidance at 0.330-0.350 EPS.Parties that wish to register for the company's conference call can do so using this link.
Iradimed (NASDAQ:IRMD - Get Free Report) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.01). Iradimed had a return on equity of 24.62% and a net margin of 26.22%. The firm had revenue of $17.45 million during the quarter. On average, analysts expect Iradimed to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Iradimed Price Performance
Shares of IRMD traded up $0.39 during trading hours on Friday, hitting $41.86. The stock had a trading volume of 27,053 shares, compared to its average volume of 51,427. The company's fifty day moving average is $42.74 and its two-hundred day moving average is $43.01. Iradimed has a 52 week low of $36.12 and a 52 week high of $51.04. The stock has a market capitalization of $529.95 million, a price-to-earnings ratio of 30.78 and a beta of 0.82.
Analyst Ratings Changes
IRMD has been the topic of several analyst reports. Singular Research reaffirmed a "buy" rating on shares of Iradimed in a report on Monday, April 1st. Roth Mkm reiterated a "buy" rating and set a $65.00 price target on shares of Iradimed in a research report on Monday. Finally, Roth Capital reiterated a "buy" rating on shares of Iradimed in a research report on Monday.
Get Our Latest Report on Iradimed
About Iradimed
(
Get Free Report)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Recommended Stories
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
